Global Huntington’s Disease Treatment Market Size, Share & Trends Analysis Report, 2018-2023 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 9, 2018--The “Huntington’s Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Therapy, Disease-modifying Therapy), By Major Markets, And Segment Forecasts, 2018 - 2023” report has been added to ResearchAndMarkets.com’s offering.
The global Huntington’s disease treatment market size is expected to be valued at USD 1.5 billion by 2023, registering a CAGR of 38.2% during the forecast period.
The market is largely driven by factors such as rapid uptake of disease-modifying therapies, increased adoption of novel therapeutics, and increase in R&D activities.
Huntington’s disease is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. Currently, only two symptom-alleviating therapies are specifically approved for this disorder: Xenazine and Austedo. Off-label medications are used extensively due to lack of approved alternatives.
The pipeline for Huntington’s disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation.
The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma’s antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
Chapter 4 Global Huntington’s Disease Treatment Market Overview
Chapter 5 Huntington’s Disease Treatment Market: Pipeline Intelligence
Chapter 6 Company ProfilesValeant Pharmaceuticals Teva Pharmaceuticals Ionis Pharmaceuticals Wave Life Sciences Horizon Pharma Prana Biotech
For more information about this report visit https://www.researchandmarkets.com/research/gd4t49/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181109005253/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH GENETICS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/09/2018 07:33 AM/DISC: 11/09/2018 07:33 AM